Quarterly Period Covered: Second quarter of fiscal year 2026 (April 1 - June 30, 2026), with year-to-date comparison to same period in 2025 Financial Statements Included: Consolidated balance sheets as of June 30, 2026 and December 31, 2025; consolidated statements of earnings for Q2 2026 and six-month period ended June 30, 2026 with year-over-year comparisons; statements of stockholders' equity…

Our analysis rates this filing NEUTRAL. Edwards Lifesciences presents an elevated but stable risk profile appropriate for a mature medical device company navigating a significant post-divestiture transition. The primary concern centers on the Critical Care business sale to Becton Dickinson, which…

Concern level: ELEVATED (5.8/10). Key factors: One high-severity risk identified: Critical Care Business Divestiture with ongoing regulatory/integration risk (severity 7/10) - Edwards retains contingent liabilities and compliance obligations through Q2 2026 and beyond following September 2024 BD sale; Derivative financial instruments and hedging exposure across interest rate, currency, and…

Notable risk changes: Critical Care segment divestiture to Becton Dickinson completed September 2024 - Edwards retains contingent liabilities and regulatory compliance obligations through Q2 2026 and beyond; Derivative financial instruments and hedging positions maintained across multiple categories (interest rate, currency, commodity) - exposure to mark-to-market volatility in current rate environment; Equity…

The model predicts EW will underperform the S&P 500 by about 0.0% over 30 days. This is model analysis for research, not investment advice.